Get the Daily Brief
Latest Biotech News
FDA approval for rare disease oral/injectable pipeline
Mirum Pharmaceuticals’ Atebrioz has received FDA approval for fibrodysplasia ossificans progressiva (FOP), extending the company’s rare-disease franchise with a third approved option for the...
Regulatory setback on oncology accelerated approval pathway
Daiichi Sankyo and Merck withdrew a lung cancer antibody-drug conjugate filing after FDA pushback, according to the report. The regulator said the companies lacked sufficient data to support...
Company-level legal outcome impacting capital expectations
Nektar Therapeutics’ stock didn’t surge as investors may have expected following a jury verdict in its favor versus Eli Lilly over the termination of a rezpegaldesleukin (rezpeg) collaboration....
Thermostable RNA vaccine formulation using AI-driven design
Researchers reported an AI-guided approach to rapidly identify thermostable mRNA–lipid nanoparticle vaccine formulations, addressing a key barrier to global distribution of mRNA platforms. Using...
LNP engineering for large RNA cargo and tissue targeting
A Nature Biotechnology report highlighted how incorporating RNA cargo size into lipid nanoparticle design can improve performance for delivery of large gene editors. In parallel, another Nature...
Self-amplifying RNA vaccine resistance to intracellular defenses
A study led by Queen Mary University of London described a viral protein strategy to overcome cellular restrictions on self-amplifying RNA (saRNA). In a Nature Communications paper, adding the...
AI-assisted clinical monitoring to reduce trial cost and inefficiency
Medable reported independent modeling results suggesting its AI-assisted clinical monitoring software can reduce trial costs by improving how monitors handle documentation and site variability....
CRISPR nuclease engineering accelerates genome editing performance
Researchers engineered a compact CRISPR nuclease (CgCas12n) into a high-performance genome-editing platform, reporting a roughly 60-fold power boost in human cells. The work, published in...
Clinical monitoring and decision support for oncology response uncertainty
A new AI-driven clinical monitoring approach aims to identify uncertainty about whether cancer patients will respond to therapy. The report focuses on metastatic non-small cell lung cancer and...
Operational readiness as a bottleneck for moving therapies to market
A commentary piece in the biotech investing ecosystem argued that scientific breakthroughs are not the limiting factor for most new companies; operational execution—GMP production, quality...
Regulatory setback for next-gen lung cancer ADC filing
Daiichi Sankyo and Merck withdrew an antibody-drug conjugate (ADC) filing for lung cancer after the FDA pushed back over an accelerated-approval evidentiary gap in the targeted population. The...
FDA nod for Mirum’s oral pill in FOP
Mirum Pharmaceuticals’ atebrioz (Atebrioz), an oral therapy for fibrodysplasia ossificans progressiva (FOP), received FDA approval, becoming the third approved drug option for the ultra-rare...
AI monitoring claims cost savings in oncology trials
Medable’s AI clinical monitoring software—Clinical Monitoring Agent—showed potential cost and efficiency benefits in an independent analysis led by researchers at Tufts Center for the Study of...
Court ruling turns Nektar’s Lilly deal dispute into a market test
Nektar Therapeutics said a jury awarded it $90 million, plus interest, after finding that Eli Lilly breached an implied covenant of good faith and fair dealing in a co-development agreement tied...
Next-gen dopamine therapy gets FDA green light
The FDA approved AbbVie’s next-generation dopamine agonist tavapadon for Parkinson’s disease, to be marketed as Juvmo. The company positions the therapy as an improvement over existing dopamine...
RNA vaccine thermal stability breakthrough
MIT researchers reported a new RNA vaccine formulation designed to withstand high temperatures, targeting one of the main logistical barriers that ultracold storage creates for broader deployment....
AI-native biotech investors refocus on clinical execution
At LSX Congress USA, Form Bio executives argued that investable AI drug discovery increasingly depends on downstream clinical development capabilities—not just faster target identification. The...
GLP-1 marketing shift from medical obesity to lifestyle positioning
Novo Nordisk is reframing GLP-1 drugs as “weight loss” products and shifting how it refers to people using them—from “patients” to “customers,” according to STAT+. The report points to global...
Operational constraint emerges as a biopharma bottleneck
A new analysis argues that breakthrough biotherapies still face a major hidden hurdle: whether companies have the operational talent and quality systems to move assets through GMP manufacturing,...
Carbon reduction therapy strategy sparks long-term arthritis interest
A long-term analysis of a randomized trial presented at ASTRO suggested that low-dose radiation may help slow progression in knee osteoarthritis. The report frames radiation—a modality better...